Results

How Fast Does Zepbound Work? Timeline of Weight Loss Results

Zepbound's biggest share of loss came in the first 24 weeks — about 13.3% to 14.5% among adherent trial participants who lost at least 5% — with a plateau typically at 24 to 36 weeks and 72-week label averages of 15.0% to 20.9% depending on dose.

Last checked September 14, 2026·9 sources cited·Wegovy Mounjaro Zepbound

Bathroom scale on a rising then flattening clay ramp with an injection pen and small clock beside it.

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

The earliest checkpoint in the trial data is week 12: in a post hoc analysis of 1,545 SURMOUNT-1 participants who took at least 75% of their doses, 82% had lost at least 5% of their body weight by that point ^[4]. The biggest share of loss came in the first 24 weeks, when adherent participants who lost at least 5% dropped about 13.3% to 14.5% of body weight on average, depending on starting BMI category ^[3]. Loss then slows, and most people reach a weight plateau between roughly 24 and 36 weeks, with median times of 24.3 weeks in the overweight group and 36.1 weeks in the class II and III obesity groups ^[3]. By 72 weeks, the FDA label reports average losses of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg in people without type 2 diabetes, compared with 3.1% on placebo ^[1].

One reason the early months look the way they do: the dose builds up slowly. Zepbound starts at 2.5 mg once weekly for 4 weeks, and that starting dose is for initiation only, not maintenance ^[1]. In SURMOUNT-1, participants reached their target dose at week 4 (5 mg), week 12 (10 mg), or week 20 (15 mg) after a 20-week escalation ^[4].

What is Zepbound and how does dosing work?

Zepbound is a once-weekly injection of tirzepatide, a single molecule that activates both the GIP and GLP-1 receptors ^[1]. It is approved, along with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity ^[1].

The label’s escalation schedule starts at 2.5 mg weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on each dose, until a maintenance dose of 5 mg, 10 mg, or 15 mg weekly is reached; 15 mg is the maximum ^[1]. The label states that treatment response and tolerability are considered when selecting the maintenance dose ^[1]. Dose decisions belong with a prescriber.

Mounjaro is the same molecule, tirzepatide. It was approved by the FDA on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes ^[2].

In the SURMOUNT-1 trial, everyone in every arm, including placebo, followed the same lifestyle program: counseling toward about a 500 kcal/day deficit and at least 150 minutes of physical activity per week ^[1]^[4].

How much weight loss happens in the first 3 to 6 months?

By week 12, most adherent participants had crossed the 5% threshold. In the post hoc analysis of 1,545 participants who received at least 75% of their assigned doses, 82% had lost at least 5% of body weight, while 18% had not ^[4].

By week 24, the 6-month mark, the loss was substantial across the board. In a separate post hoc analysis of 1,438 adherent participants who lost at least 5% of body weight, mean weight change from baseline to week 24 was -13.4% for overweight, -14.5% for class I obesity, -14.3% for class II, and -13.3% for class III ^[3]. The greatest percent reduction occurred in the first 24 weeks, and the amount was similar regardless of starting BMI category ^[3].

From week 24 to week 72, additional loss was smaller and did differ by BMI group: -4.6% for overweight, versus -7.0% for class I, -8.8% for class II, and -9.7% for class III obesity ^[3].

What are the results at 72 weeks by dose?

The FDA label reports intention-to-treat results, which include everyone randomly assigned whether or not they stayed on the drug. In Study 1 (adults with obesity or overweight, no type 2 diabetes), the 72-week averages were ^[1]:

Group	Mean % weight change	Lost ≥5%	Lost ≥20%
Placebo	-3.1%	34.5%	3.1%
Zepbound 5 mg	-15.0%	85.1%	30.0%
Zepbound 10 mg	-19.5%	88.9%	50.1%
Zepbound 15 mg	-20.9%	90.9%	56.7%

In Study 2, which enrolled adults with type 2 diabetes, the label reports -3.2% on placebo, -12.8% on 10 mg, and -14.7% on 15 mg at 72 weeks ^[1].

Lilly’s press release for SURMOUNT-1 reports a different set of numbers, the efficacy estimand: 16.0% on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, versus 2.4% on placebo ^[2]. The estimand and the label’s intention-to-treat figures answer slightly different statistical questions, so they should not be mixed in one comparison. On the efficacy estimand, 39.7% of people on 15 mg lost at least 25% of their body weight ^[2].

When does Zepbound weight loss slow or plateau?

During successful obesity treatment, two phases are often observed: an initial weight-loss phase followed by a weight-maintenance phase, and the plateau is the transition between them ^[3]. In the post hoc analysis, a plateau was defined as a weight change under 5% over a 12-week interval and every later 12-week interval ^[3]. Median time to plateau in SURMOUNT-1 was 24.3 weeks for overweight, 26.0 weeks for class I obesity, and 36.1 weeks for both class II and class III obesity ^[3].

By week 72, 90.2% of the overweight group, 88.9% of class I, 87.6% of class II, and 87.8% of class III had reached a plateau ^[3]. Roughly 90% in every group, in other words. Higher doses of tirzepatide (10 and 15 mg), younger age, and female sex were linked with reaching a plateau later, and a longer time to plateau went along with greater total weight reduction ^[3]. Results in SURMOUNT-4 were similar ^[3].

These plateau figures come from a post hoc subset: adherent participants who received at least 75% of doses and lost at least 5% of body weight, not all trial participants ^[3]. They are group averages, and individual timing varies.

Is it normal to lose little by week 12?

It happens to about one in five adherent participants. In the post hoc analysis of SURMOUNT-1, 278 of 1,545 participants (18%) had lost less than 5% of body weight at week 12 ^[4]. Compared with early responders, these late responders were more often male (45% vs. 30%), and had higher starting weight (110.2 vs. 103.6 kg) and BMI (39.1 vs. 37.7) ^[4].

Many of them caught up. Of the late responders, 194 (70%) reached at least 5% loss by week 24, and 250 (90%) reached it by week 72; their mean time to a 5% loss was 24.8 weeks ^[4]. The authors note that some obesity management guidelines published in 2015 suggest stopping a medication if 5% loss is not achieved within 12 weeks, and that continuing treatment well beyond 12 weeks may allow more patients to reach meaningful loss ^[4]. Whether to continue is a decision for a prescriber.

How do Zepbound results compare with Wegovy?

In the head-to-head SURMOUNT-5 trial, 751 adults with obesity but without type 2 diabetes received the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (Wegovy, 1.7 or 2.4 mg) for 72 weeks ^[5]. Average weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm ^[5]. Gastrointestinal events were the most common side effects in both groups, mostly mild to moderate and occurring primarily during dose escalation ^[5].

A 2026 meta-analysis of 10 head-to-head studies with 41,381 participants found tirzepatide associated with 4.28 percentage points more weight loss and 4.43 kg more absolute loss than semaglutide, with no difference between the drugs at the 5% loss threshold ^[6]. The same analysis found serious adverse events more frequent with tirzepatide (relative risk 1.83) but no significant difference in discontinuation due to adverse events ^[6].

What about side effects during the early months?

Gastrointestinal events are the most common problem, and they cluster in the escalation period. In SURMOUNT-1, GI events were generally mild to moderate and usually occurred during dose escalation ^[2]. In the label’s pooled analysis of Studies 1 and 2, nausea affected 25% on 5 mg, 29% on 10 mg, and 28% on 15 mg, versus 8% on placebo ^[1].

Discontinuation due to adverse reactions occurred in 4.8%, 6.3%, and 6.7% of patients on 5, 10, and 15 mg versus 3.4% on placebo, mostly in the first few months and mostly due to GI reactions ^[1]. Overall discontinuation of study drug in Study 1 was 14.3%, 16.4%, and 15.1% on the three doses versus 26.4% on placebo ^[1].

How much of the weight lost is fat versus muscle?

In a DXA scanning substudy of 160 SURMOUNT-1 participants, weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9% on tirzepatide by week 72, versus -5.3%, -8.2%, and -2.6% on placebo ^[7]. About 75% of the weight lost was fat and about 25% was lean mass, in both the tirzepatide and placebo groups, and that split stayed consistent across most subgroups ^[7].

What happens after stopping Zepbound?

SURMOUNT-4 enrolled 783 adults in a 36-week open-label lead-in on a maximum tolerated dose of 10 or 15 mg; 670 were then randomized to continue tirzepatide or switch to placebo for 52 more weeks ^[8]. The mean loss during the lead-in was 20.9% ^[8].

From week 36 to week 88, those who continued lost another 5.5% on average, while those switched to placebo regained 14.0%, a treatment difference of -19.4 percentage points ^[8]. At week 88, 89.5% of those who continued had kept at least 80% of their lead-in loss, versus 16.6% of those switched to placebo; total change from week 0 was -25.3% versus -9.9% ^[8].

A post hoc analysis of 308 placebo-switched participants who had lost at least 10% during the lead-in found that 254 (82.5%) regained at least 25% of that loss by week 88, and greater regain went with greater reversal of improvements in waist circumference, blood pressure, non-HDL cholesterol, and glycemic measures ^[9].

Why are real-world results lower than trial results?

Outside trials, results tend to be smaller. A Cleveland Clinic cohort of 7,881 adults without type 2 diabetes who started injectable semaglutide or tirzepatide between 2021 and 2023 (1,772 on tirzepatide, 6,109 on semaglutide) had a mean one-year weight loss of 8.7% pooled across both drugs ^[10]. Loss was 3.6% for those who discontinued early (within 3 months), 6.8% for late discontinuation, and 11.9% for those with no discontinuation; 80.8% of the cohort was on low maintenance doses ^[10]. The authors attribute the gap from phase 3 trials to more discontinuation and lower doses, and tirzepatide was associated with higher odds of achieving 10% loss ^[10].

A two-center study of adults with BMI 35 or higher found tirzepatide total weight loss of 9.1% at 1 year and 10.8% at 2 years, and 11.7% at 1 year among those with a full year of continuous prescriptions ^[11].

Sources

Frequently asked questions

How long before Zepbound starts working?

The earliest checkpoint in the trial data is week 12: among 1,545 adherent SURMOUNT-1 participants, 82% had lost at least 5% of body weight by then. The greatest percent reduction came in the first 24 weeks of treatment.

How much weight loss happens in the first 3 to 6 months?

By week 12, 82% of adherent participants had lost at least 5% of body weight. By week 24, the 6-month mark, adherent participants who lost at least 5% averaged -13.3% to -14.5% depending on BMI category, with the greatest percent reduction occurring in the first 24 weeks.

Is it normal to lose little at 12 weeks?

Yes, it occurs in about 18% of adherent participants. Of those late responders, 70% reached at least 5% loss by week 24 and 90% by week 72, with a mean time of 24.8 weeks to reach 5%. Decisions about continuing treatment belong with a prescriber.

When does Zepbound weight loss plateau?

In a post hoc analysis of adherent participants who lost at least 5%, median time to plateau was 24.3 weeks for overweight, 26.0 weeks for class I obesity, and 36.1 weeks for class II and III obesity; roughly 90% in each group had plateaued by week 72. A plateau is the transition from a weight-loss phase to a weight-maintenance phase.

Does a higher dose mean more weight loss?

In the label's intention-to-treat results at 72 weeks, average loss was 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, versus 3.1% on placebo. Higher doses were linked with a later plateau, and a later plateau went with greater total reduction. Dose selection is a prescriber's decision.

Is Mounjaro the same as Zepbound?

Both contain tirzepatide. Mounjaro was FDA-approved on May 13, 2022, for glycemic control in adults with type 2 diabetes, while Zepbound is approved for weight reduction and long-term maintenance, and for obstructive sleep apnea in adults with obesity.

How do Zepbound results compare with Wegovy?

In the 72-week SURMOUNT-5 head-to-head trial, tirzepatide produced -20.2% average weight loss versus -13.7% with semaglutide. A 2026 meta-analysis of 10 studies found 4.28 percentage points more loss with tirzepatide, but also more frequent serious adverse events (relative risk 1.83).

Why are real-world results lower than trial results?

A Cleveland Clinic cohort of 7,881 adults on semaglutide or tirzepatide averaged 8.7% loss at one year pooled across both drugs, with 80.8% on low maintenance doses; the authors say the gap from trials is likely due to more discontinuation and lower doses. A two-center study found 9.1% tirzepatide loss at 1 year.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.